Update on KHK4083
Inflammatory Skin Disease Summit (ISDS) 2021 Presentation

November 5, 2021

Kyowa Kirin Co., Ltd.
This document contains certain forward-looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward-looking statements are based upon information available to the company at the present time and upon reasonable assumptions made by the company in making its forecasts, but the actual results in practice may differ substantially due to uncertain factors.

These uncertain factors include, but are not limited to, potential risks of the business activities in the pharmaceutical industry in Japan and overseas, intellectual property risks, risk of side effects, regulatory risks, product defect risks, risks of changes to the prices for raw materials, risks of changes to market prices, as well as risks of changes to foreign exchange rates and financial markets.

This document is used only for the purpose of providing the information to investors. Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or medical advice.
Treatment with KHK4083/AMG 451, an antagonist of OX40, induces durable modulation of atopic dermatitis (AD)-related blood/skin biomarkers

Emma Guttman-Yassky,1 Munetake Shimabe,2 Rui Ohashi,3 Takeshi Matsui,2 Ehsanollah Esfandiari,3,4 Etsuji Kaneko2

1Icahn School of Medicine at Mount Sinai Hospital, New York, USA; 2R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan; 3Kyowa Kirin, Inc., Princeton, New Jersey, USA; 4Kyowa Kirin International Plc, London, UK
**KHK4083/AMG 451 targets OX40 as a potential novel target for AD treatment**

- The OX40–OX40L axis plays a critical role in long-lasting T-cell responses
  - OX40 is expressed by activated T cells after antigen recognition and binds OX40L on antigen-presenting cells (APCs), facilitating the effector function of T cells
- KHK4083/AMG 451 is a fully human, anti-OX40, non-fucosylated IgG1 mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC)\(^1\) that acts by
  - Depleting activated T cells\(^2\)
  - Blocking T-cell clonal expansion and memory T-cell formation\(^2\)

---

**Mechanism of action of KHK4083\(^2\)**

- **Depleting activated T cells**
- **Blocking T-cell clonal expansion and memory T-cell formation**

---

AD, atopic dermatitis; ADCC, antibody-dependent cellular cytotoxicity; APC, antigen-presenting cell; CD28, cluster of differentiation 28; IgG, immunoglobulin G; MHC, major histocompatibility complex; mAb, monoclonal antibody; TCR, T-cell receptor; Th2, T-helper 2

Objectives

- In a randomized, double-blind, placebo-controlled phase 2b study, we assessed the efficacy and safety of 4 dose regimens of KHK4083/AMG 451 in patients with moderate-to-severe AD
- We also monitored AD-related biomarkers (in blood) and target engagement biomarkers (in blood and skin)
Phase 2 Study Design (NCT03703102)

**Primary efficacy endpoint**
- % change in EASI score from BL to W16

**Secondary efficacy endpoints**
- Reduction of ≥50%, ≥75%, and ≥90% in EASI score (EASI 50/75/90) from BL
- Achievement of an IGA score of 0/1 and a reduction of ≥2 points from BL (IGA0/1)
- Achievement of a reduction of ≥4 points in Pruritus-NRS score from BL

**Safety evaluations**
- Adverse events

**Exploratory endpoints**
- Percent change from BL over time in Blood samples (All subjects):
  - TARC
  - Serum total IgE
  - IL-22

**Blood and skin biopsy** (Clinical biomarker substudy: subjects from Japan who provided additional consent)
- Total OX40+ helper T cells in blood
- Unoccupied OX40+ helper T cells in blood
- OX40+ cells in skin

**Screening**
- Adults with chronic AD
- EASI ≥16; IGA ≥3;
- BSA ≥10%
- Inadequate response or intolerance to topical AD medications

**Randomization**
- (1:1:1:1:1)
- n=50 in each group

**Location**
- US, Japan, Germany, and Canada

**Treatment A**
- (Up to Week 18)
- Placebo

**Treatment B**
- (Week 18-Week 36)
- KHK4083 600 mg SC Q2W
- KHK4083 150 mg SC Q4W
- KHK4083 300 mg SC Q2W
- KHK4083 600 mg SC Q2W

**Follow-up**
- Follow-up every 4 weeks

**Sample collections**
- BL visit/W0
Baseline Demographics and Disease Characteristics (Safety Analysis Set)

All baseline parameters were generally well-balanced among the treatment groups

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>KHK4083 150 mg Q4W N=54</th>
<th>KHK4083 600 mg Q4W N=53</th>
<th>KHK4083 300 mg Q2W N=55</th>
<th>KHK4083 600 mg Q2W N=54</th>
<th>Placebo/ KHK4083 600 mg Q2W N=57</th>
<th>Total N=273</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>37.4 ± 13.6</td>
<td>38.9 ± 14.6</td>
<td>37.5 ± 14.1</td>
<td>37.3 ± 16.3</td>
<td>38.7 ± 14.4</td>
<td>38.0 ± 14.5</td>
</tr>
<tr>
<td>Sex, male, n (%)</td>
<td>37 (68.5)</td>
<td>31 (58.5)</td>
<td>31 (56.4)</td>
<td>30 (55.6)</td>
<td>31 (54.4)</td>
<td>160 (58.6)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian: Japanese</td>
<td>30 (55.6)</td>
<td>28 (52.8)</td>
<td>32 (58.2)</td>
<td>30 (55.6)</td>
<td>30 (52.6)</td>
<td>150 (54.9)</td>
</tr>
<tr>
<td>Asian: Other</td>
<td>6 (11.1)</td>
<td>4 (7.5)</td>
<td>5 (9.1)</td>
<td>3 (5.6)</td>
<td>7 (12.3)</td>
<td>25 (9.2)</td>
</tr>
<tr>
<td>Black or African American</td>
<td>3 (5.6)</td>
<td>1 (1.9)</td>
<td>2 (3.6)</td>
<td>1 (1.9)</td>
<td>6 (10.5)</td>
<td>13 (4.8)</td>
</tr>
<tr>
<td>White</td>
<td>14 (25.9)</td>
<td>20 (37.7)</td>
<td>16 (29.1)</td>
<td>20 (37.0)</td>
<td>14 (24.6)</td>
<td>84 (30.8)</td>
</tr>
<tr>
<td>Other</td>
<td>1 (1.9)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Body mass index at screening, kg/m²</td>
<td>24.99 ± 4.81</td>
<td>24.69 ± 5.69</td>
<td>26.69 ± 7.24</td>
<td>25.19 ± 6.49</td>
<td>24.26 ± 5.23</td>
<td>25.16 ± 5.97</td>
</tr>
<tr>
<td>Duration from diagnosis of AD to randomization, years</td>
<td>6.47 ± 6.59</td>
<td>8.40 ± 8.32</td>
<td>8.59 ± 9.58</td>
<td>6.42 ± 5.69</td>
<td>6.41 ± 5.98</td>
<td>7.26 ± 7.32</td>
</tr>
<tr>
<td>Severity of AD - IGA, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>30 (55.6)</td>
<td>28 (52.8)</td>
<td>30 (54.5)</td>
<td>29 (53.7)</td>
<td>31 (54.4)</td>
<td>148 (54.2)</td>
</tr>
<tr>
<td>4</td>
<td>24 (44.4)</td>
<td>25 (47.2)</td>
<td>25 (45.5)</td>
<td>25 (46.3)</td>
<td>26 (45.6)</td>
<td>125 (45.8)</td>
</tr>
<tr>
<td>Pruritus-NRS score</td>
<td>7.8 ± 1.6</td>
<td>7.5 ± 2.3</td>
<td>7.5 ± 1.6</td>
<td>7.6 ± 1.9</td>
<td>7.2 ± 2.3</td>
<td>7.5 ± 2.0</td>
</tr>
<tr>
<td>EASI score</td>
<td>32.8 ± 13.1</td>
<td>32.5 ± 12.7</td>
<td>32.2 ± 13.4</td>
<td>31.1 ± 11.8</td>
<td>29.2 ± 13.3</td>
<td>31.5 ± 12.8</td>
</tr>
<tr>
<td>SCORAD score</td>
<td>68.75 ± 12.57</td>
<td>69.44 ± 13.64</td>
<td>68.52 ± 14.36</td>
<td>68.79 ± 14.36</td>
<td>66.35 ± 14.05</td>
<td>68.34 ± 13.76</td>
</tr>
<tr>
<td>Percent BSA</td>
<td>59.5 ± 23.7</td>
<td>59.1 ± 25.2</td>
<td>56.8 ± 21.8</td>
<td>55.3 ± 23.4</td>
<td>54.3 ± 23.5</td>
<td>56.9 ± 23.5</td>
</tr>
<tr>
<td>Previous use of biological products for treatment of AD, n (%)</td>
<td>7 (13.0)</td>
<td>5 (9.4)</td>
<td>8 (14.5)</td>
<td>8 (14.8)</td>
<td>9 (15.8)</td>
<td>37 (13.6)</td>
</tr>
</tbody>
</table>

AD, atopic dermatitis; BSA, body surface area; EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; NRS, Numerical Rating Scale; SCORAD, Severity scoring of atopic dermatitis; Q2W, every 2 weeks; Q4W, every 4 weeks
Proportion of Patients Who Achieved EASI-75 (Non-responder Imputation, Full Analysis Set)

Proportions of EASI-75 responders at Week 16 were significantly higher in all KHK4083-treated cohorts versus placebo.

**p<0.001 versus placebo, assessed at Week 16

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Week 16</th>
<th>Week 24</th>
<th>Week 36</th>
</tr>
</thead>
<tbody>
<tr>
<td>KHK4083 150 mg Q4W, %</td>
<td>44.2**</td>
<td>48.1</td>
<td>51.9</td>
</tr>
<tr>
<td>KHK4083 600 mg Q4W, %</td>
<td>40.4**</td>
<td>53.8</td>
<td>57.7</td>
</tr>
<tr>
<td>KHK4083 300 mg Q2W, %</td>
<td>53.8**</td>
<td>65.4</td>
<td>63.5</td>
</tr>
<tr>
<td>KHK4083 600 mg Q2W, %</td>
<td>38.9**</td>
<td>53.7</td>
<td>57.4</td>
</tr>
<tr>
<td>Placebo/KHK4083 600 mg Q2W, %</td>
<td>10.5</td>
<td>19.3</td>
<td>35.1</td>
</tr>
</tbody>
</table>

**p<0.001 versus placebo, assessed at Week 16
Durability of EASI-75 Response After Treatment Discontinuation in Subjects who Achieved EASI-75 at Week 36

EASI-75 response was durable even after discontinuation of KHK4083 at Week 36

If patients use topical or systemic rescue therapy or dropped during the study in follow-up period, they are not treated as relapse as long as their EASI score meets EASI-75 criteria before taking rescue therapy and is displayed as “+”.

The KM curve censored 37 (26%) EASI 75 responders who received rescue therapy during off-treatment.
## TEAEs – Treatment A (Safety Analysis Set)

In Treatment A, 81% TEAEs occurred in KHK4083 groups versus 72% in the placebo group

<table>
<thead>
<tr>
<th>Category</th>
<th>KHK4083 150 mg Q4W N=54</th>
<th>KHK4083 600 mg Q4W N=53</th>
<th>KHK4083 300 mg Q2W N=55</th>
<th>KHK4083 600 mg Q2W N=54</th>
<th>KHK4083 Total N=216</th>
<th>Placebo N=57</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any TEAEs</td>
<td>37 (68.5)</td>
<td>45 (84.9)</td>
<td>47 (85.5)</td>
<td>46 (85.2)</td>
<td>175 (81.0)</td>
<td>41 (71.9)</td>
</tr>
<tr>
<td>Serious TEAEs</td>
<td>3 (5.6)</td>
<td>1 (1.9)</td>
<td>3 (5.5)</td>
<td>1 (1.9)</td>
<td>8 (3.7)</td>
<td>1 (1.8)</td>
</tr>
<tr>
<td>TEAEs leading to treatment discontinuation</td>
<td>5 (9.3)</td>
<td>3 (5.7)</td>
<td>7 (12.7)</td>
<td>4 (7.4)</td>
<td>19 (8.8)</td>
<td>12 (21.1)</td>
</tr>
<tr>
<td>All deaths</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TEAEs with severity grade of ≥3</td>
<td>6 (11.1)</td>
<td>1 (1.9)</td>
<td>5 (9.1)</td>
<td>4 (7.4)</td>
<td>16 (7.4)</td>
<td>2 (3.5)</td>
</tr>
</tbody>
</table>
TARC: Median % Change From Baseline at Each Scheduled Visit
(Safety Analysis Set)

TARC levels clearly reduced in all KHK4083 groups. In the placebo/KHK4083 600 mg Q2W group, TARC reached almost the same levels as those in other KHK4083 groups around Week 32. TARC reduction was near maximum at Week 16 in all KHK4083 groups and sustained during off-treatment after Week 36.
IgE: Median % Change From Baseline at Each Scheduled Visit (Safety Analysis Set)

Total IgE was continuously reduced after Week 16 in KHK4083 groups and reached 50% reduction. This trend continued during off-treatment after Week 36 except in the KHK4083 150 mg Q4W group.

Data presented from safety analysis set, which included patients who received at least 1 dose of investigational product; 273 of the 274 randomized patients were included in the safety analysis set.
IL-22: Median % Change From Baseline at Each Scheduled Visit (Safety Analysis Set)

IL-22 reduction was confirmed at Week 16 in all KHK4083 groups and continued after Week 16. The reduction was maintained during off-treatment after Week 36.

Data presented from safety analysis set, which included patients who received at least 1 dose of investigational product; 273 of the 274 randomized patients were included in the safety analysis set.

© Kyowa Kirin Co., Ltd.
Total OX40+ Helper T Cells in Peripheral Blood: Median % Change From Baseline at Each Scheduled Visit (Clinical Biomarker Statistical Analysis Set)

KHK4083 quickly showed reduction in OX40+ helper T cells in all KHK4083 groups. This reduction persisted during off-treatment after Week 36.

Data presented from clinical biomarker statistical analysis set, which included 26 Japanese patients who provided additional consent.

© Kyowa Kirin Co., Ltd.
Unoccupied OX40+ Helper T Cells in Peripheral Blood: Median % Change From Baseline at Each Scheduled Visit (Clinical Biomarker Statistical Analysis Set)

Unoccupied OX40+ helper T cells were detected at very low levels from Week 1 in all KHK4083 groups and retained at least 10 weeks after the last dose of KHK4083 at Week 34. The reductions persisted through Week 52 in the group randomized to 300 mg Q2W.

Data presented from clinical biomarker statistical analysis set, which included 26 Japanese patients who provided additional consent.
OX40+ Cells in the Upper Dermis (Skin Biopsy Lesion): Median % Change From Baseline at Each Scheduled Visit (Clinical Biomarker Statistical Analysis Set)

- OX40+ cells were removed from the upper dermis.
- Faster reduction of OX40+ cells was observed in the 300 mg Q2W and 600 mg Q4W groups.
- Removal of OX40+ cells was sustained during the off-treatment period (through Week 52), except in the 150 mg Q4W group.

<table>
<thead>
<tr>
<th>Treatment A</th>
<th>Treatment B</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Placebo-controlled period)</td>
<td>(All groups received KHK4083)</td>
<td>(After KHK4083 discontinuation)</td>
</tr>
<tr>
<td>KHK4083 150 mg Q4W n=4</td>
<td>KHK4083 600 mg Q4W n=5</td>
<td>KHK4083 300 mg Q2W n=7</td>
</tr>
<tr>
<td>KHK4083 600 mg Q2W n=6</td>
<td>KHK4083 600 mg Q2W</td>
<td>Placebo/KHK4083 600 mg Q2W n=4</td>
</tr>
</tbody>
</table>

Data presented from clinical biomarker statistical analysis set, which included 26 Japanese patients who provided additional consent.

© Kyowa Kirin Co., Ltd.
Conclusions

In patients with moderate-to-severe AD

- KHK4083/AMG 451 groups demonstrated significant improvements in efficacy parameters, compared with the placebo group, at Week 16 and beyond

- KHK4083/AMG 451 induced significant modulation of AD-related biomarkers, including reduction in OX40+ T cells, TARC, IgE, and IL-22 in blood, that parallel the improvement in clinical measures observed across all KHK4083 groups at Week 16 and beyond
  - The sustained inhibition/depletion of OX40+ helper T cells (the drug target) may link closely to longer control of active disease following the withdrawal of treatment and potentially with a disease-modifying effect

- KHK4083/AMG 451 was well tolerated and did not show any new safety concerns

- KHK4083/AMG 451 may be a novel treatment option in patients with moderate-to-severe AD